Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs
Yufeng Xiao, Jia Wang, Lisa Zhao, et al.
Chemical Communications (2020) Vol. 56, Iss. 68, pp. 9866-9869
Open Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

Class I histone deacetylases (HDAC1–3) are histone lysine delactylases
Carlos Moreno–Yruela, Di Zhang, Wei Wei, et al.
Science Advances (2022) Vol. 8, Iss. 3
Open Access | Times Cited: 327
Proteolysis-targeting chimeras (PROTACs) in cancer therapy
Xinyi Li, Wenchen Pu, Qingquan Zheng, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 187
Targeted protein degradation: A promise for undruggable proteins
Kusal T. G. Samarasinghe, Craig M. Crews
Cell chemical biology (2021) Vol. 28, Iss. 7, pp. 934-951
Open Access | Times Cited: 184
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
Ming He, Chao-Guo Cao, Zhihao Ni, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 168
An overview of PROTACs: a promising drug discovery paradigm
Liu Zi, Mingxing Hu, Yang Yu, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 148
Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives
Robert Jenke, Nina Reßing, Finn K. Hansen, et al.
Cancers (2021) Vol. 13, Iss. 4, pp. 634-634
Open Access | Times Cited: 137
Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang Tao, Fengli Wang, Reham M. Elhassan, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 6, pp. 2425-2463
Open Access | Times Cited: 82
Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies
Ailin Zhao, Hui Zhou, Jinrong Yang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 62
HDAC-targeting epigenetic modulators for cancer immunotherapy
Binbin Cheng, Wei Pan, Yao Xiao, et al.
European Journal of Medicinal Chemistry (2024) Vol. 265, pp. 116129-116129
Closed Access | Times Cited: 30
Developments of CRBN-based PROTACs as potential therapeutic agents
Chao Wang, Yujing Zhang, Yudong Wu, et al.
European Journal of Medicinal Chemistry (2021) Vol. 225, pp. 113749-113749
Closed Access | Times Cited: 95
CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers
Aaron Waddell, Haojie Huang, Daiqing Liao
Cancers (2021) Vol. 13, Iss. 12, pp. 2872-2872
Open Access | Times Cited: 71
Chemo-proteomics exploration of HDAC degradability by small molecule degraders
Yuan Xiong, Katherine A. Donovan, Nicholas A. Eleuteri, et al.
Cell chemical biology (2021) Vol. 28, Iss. 10, pp. 1514-1527.e4
Open Access | Times Cited: 67
A bibliometric analysis of PROTAC from 2001 to 2021
Deping Li, Dongmin Yu, Yan Li, et al.
European Journal of Medicinal Chemistry (2022) Vol. 244, pp. 114838-114838
Closed Access | Times Cited: 65
Medicinal chemistry updates of novel HDACs inhibitors (2020 to present)
Xingrui He, Zi Hui, Li Xu, et al.
European Journal of Medicinal Chemistry (2021) Vol. 227, pp. 113946-113946
Closed Access | Times Cited: 57
Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells
Joshua P. Smalley, India M. Baker, Wiktoria A. Pytel, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 7, pp. 5642-5659
Open Access | Times Cited: 56
HDAC Inhibitors: Innovative Strategies for Their Design and Applications
Mateusz Daśko, Beatriz de Pascual‐Teresa, Irene Ortín, et al.
Molecules (2022) Vol. 27, Iss. 3, pp. 715-715
Open Access | Times Cited: 44
Recent Advances in PROTACs for Drug Targeted Protein Research
Tingting Yao, Heng Xiao, Hong Wang, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 18, pp. 10328-10328
Open Access | Times Cited: 43
Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity
Laura Sinatra, Jing Yang, Julian Schliehe‐Diecks, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16860-16878
Open Access | Times Cited: 42
Selective degradation of histone deacetylase 8 mediated by a proteolysis targeting chimera (PROTAC)
Jiranan Chotitumnavee, Yasunobu Yamashita, Yukari Takahashi, et al.
Chemical Communications (2022) Vol. 58, Iss. 29, pp. 4635-4638
Closed Access | Times Cited: 40
PROTACs: Novel tools for improving immunotherapy in cancer
Shizhe Li, Ting Chen, Jinxin Liu, et al.
Cancer Letters (2023) Vol. 560, pp. 216128-216128
Closed Access | Times Cited: 25
Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies
Xiaopeng Peng, Zhihao Hu, Limei Zeng, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 2, pp. 533-578
Open Access | Times Cited: 25
Unlocking the potential of PROTACs: A comprehensive review of protein degradation strategies in disease therapy
Ritesh P. Bhole, Payal R. Kute, Rupesh V. Chikhale, et al.
Bioorganic Chemistry (2023) Vol. 139, pp. 106720-106720
Closed Access | Times Cited: 23
The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods
Antonio Curcio, Roberta Rocca, Stefano Alcaro, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 620-620
Open Access | Times Cited: 14
USP7 as an emerging therapeutic target: A key regulator of protein homeostasis
Ning-Jie Guo, Bo Wang, Yu Zhang, et al.
International Journal of Biological Macromolecules (2024) Vol. 263, pp. 130309-130309
Closed Access | Times Cited: 12
Degraders in epigenetic therapy: PROTACs and beyond
Xing‐Jie Dai, Shi‐Kun Ji, Meng‐Jie Fu, et al.
Theranostics (2024) Vol. 14, Iss. 4, pp. 1464-1499
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top